Colorectal cancer
Conditions
Interventions
experimental group:ERAS method
control group:traditional method for intestinal preparation
Sponsors
Zhujiang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients with no previous colorectal surgery history; 2. Patients aged 18-90, male or non pregnant, lactating female; 3. All patients were operated by the same surgeon; 4. Nrs2002 score = 35 g / L, hemoglobin >= 100 g / L; 5. For the objects with good organ function, biochemical examination meets the following conditions: ALT <= 2.5 x ULN, AST <= 2.5 x ULN, total bilirubin <= 1.5 x ULN, creatinine <= 1.5 x ULN; 6. Patients with colorectal leakage score (CLS) less than or equal to 30; 7. Patients without contraindications for bowel preparation, such as chronic renal insufficiency and cardiac insufficiency; 8. Patients who voluntarily sign informed consent;
Exclusion criteria
Exclusion criteria: 1. Patients after new adjuvant treatment. 2. Patients whose colonoscopy was blocked by tumor and could not pass through intestinal cavity before operation or whose other data were incomplete. 3. Patients with multiple primary colorectal cancer or more than 2 times of intestinal anastomosis during operation. 4. Patients with intestinal obstruction, intestinal perforation and gastrointestinal bleeding before operation. 5. Patients with serious or uncontrolled internal diseases and infection (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, uncontrolled hypertension, COPD, chronic renal insufficiency, etc.); 6. Patients with obesity or excessive drinking, BMI >= 30 kg / m2. 7. Patients with other malignant tumor history in the past 5 years (excluding cured basal cell carcinoma, cervical carcinoma in situ, localized prostate cancer treated by surgery or breast ductal carcinoma in situ removed by surgery). 8. Patients with long-term use of immunosuppressants or steroids, or drug abuse and medical, psychological or social conditions may interfere with patients' participation in the study or affect the evaluation of the results of the study; 9. Patients with severe ulcerative colitis or congenital megacolon. 10. Patients with natural and recombinant HGF, glycerin, mannitol and allergic history. 11. Patients with poor blood glucose control and HbA1c >= 10 g / L. 12. Patients who participated in other clinical trials in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| white blood cell;Reactive protein;Procalcitonin;Gut flora;Anastomotic healing;Anastomotic microcirculation;Enterography; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine;Liver and kidney function;Tumor markers;Tumor status assessment;Anastomotic healing;Anastomotic healing; | — |
Countries
China
Contacts
Public ContactChunhui Cui
Zhujiang Hospital of Southern Medical University
Outcome results
None listed